This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
The name of the drug involved in this research study is:
-cosibelimab (a type of an anti-PD-L1 antibody)

Start Date01 Jul 2026

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT07318324

/ Not yet recruitingPhase 1IIT

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.

Start Date03 Jun 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT07144150

/ RecruitingNot Applicable

Advance Evero™ 18 Everolimus-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter Versus Paclitaxel-coated Ballons in Patients With Femoropopliteal Disease (EVERO Trial)

The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon [DCB]) in the treatment of the femoropopliteal artery lesions in patients with peripheral arterial disease (PAD). Specifically, the Randomized-Controlled Trial (RCT) is designed to demonstrate non-inferior safety and non-inferior effectiveness of the Evero DCB when compared to commercially available paclitaxel DCBs (pDCBs).

Start Date01 May 2026

Sponsor / Collaborator

Cook Research Inc

100 Clinical Results associated with Everolimus

100 Translational Medicine associated with Everolimus

100 Patents (Medical) associated with Everolimus

7,712

Literatures (Medical) associated with Everolimus

31 Dec 2026·ANNALS OF MEDICINE

Comparative effectiveness of percutaneous coronary intervention strategies for coronary small-vessel disease: a network meta-analysis of randomized trials

Review

Author: Du, Zhiyan ; Xu, Yixin ; Fan, Chao ; Wang, ZhiLong ; Jiang, Zhihui ; Wu, Tingting ; Zheng, Yingying ; Lv, Mingming ; Adilijiang, Adilai. ; Pan, Ying ; Bai, Bingxin ; Deng, Changjiang ; Xie, Xiang

BACKGROUND:

Coronary small-vessel disease (SVD) remains challenging for percutaneous coronary intervention (PCI) because small lumens magnify restenosis and ischemic risk. Multiple devices are available, yet their comparative performance is uncertain. This study evaluated and ranked PCI strategies for SVD.

METHODS:

A systematic review and network meta-analysis was conducted in accordance with PRISMA. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar were searched from inception to 15 August 2025. Eligible studies were English-language randomized controlled trials enrolling adults with angiographic SVD defined as reference vessel diameter ≤3.0 mm, comparing PCI strategies, and reporting target lesion revascularization (TLR), binary restenosis (BR), or myocardial infarction (MI). A frequentist random-effects network meta-analysis generated odds ratios (ORs) with 95% confidence intervals (CIs) and treatment rankings using the surface under the cumulative ranking curve (SUCRA).

RESULTS:

Thirty-nine trials including 14,503 patients met the criteria. For TLR (37 studies; 11,980 patients), the highest SUCRA values were observed with sirolimus-eluting stents (SES 90.1%), zotarolimus-eluting stents (ZES 83.9%), and everolimus-eluting stents (EES 82.2%). For BR (32; 6,468), SES, ZES, and paclitaxel-coated balloons (DCB-PTX) ranked highest (95.0%, 80.0%, and 78.3%). For MI (37; 11,602), SES, DCB-PTX, and ZES ranked highest (79.0%, 78.7%, and 68.5%). Representative effects showed SES reduced TLR versus bare-metal stents (BMS) (OR, 0.25; 95% CI, 0.15-0.43) and MI versus BMS (OR, 0.41; 95% CI, 0.21-0.79). Conventional approaches such as BMS, plain old balloon angioplasty (POBA), and gold-plated balloon angioplasty (GPBA) ranked lowest across outcomes.

CONCLUSION:

SES provides the most consistent clinical benefit for coronary SVD. ZES, EES, and DCB-PTX are effective alternatives in selected settings, whereas BMS, POBA, and GPBA are less effective. These findings offer comparative evidence to guide device selection in SVD.

01 May 2026·CANCER LETTERS

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial

Article

Author: Ying, Jianming ; Ma, Fei ; Fan, Ying ; Tan, Yujing ; Luo, Yang ; Xue, Xuemin ; Wang, Bingzhi ; Chen, Shanshan ; Lan, Bo ; Wang, Jiayu ; Xu, Binghe ; Ji, Danyang ; Xue, Liyan

Breast cancer is the most commonly diagnosed cancer in women globally. Our previous MIRACLE trial (NCT02313051) demonstrated that everolimus plus letrozole (E + L) significantly improves progression-free survival compared with letrozole (L) monotherapy in premenopausal patients with endocrine therapy-resistant, hormone receptor-positive, HER2-non-amplified advanced breast cancer. This study aims to investigate spatially resolved biomarkers linked to survival benefits from E + L to guide precision therapies. Patients from MIRACLE were stratified by overall survival (OS ≤ 3 vs. >3 years). Spatial Whole Transcriptome Atlas analysis was used to evaluate tumor-, immune-, and stroma-specific gene expression, co-expression network patterns, and survival correlations. Among patients with shorter survival (OS ≤ 3 years), we identified a distinctive gene interaction network characterized by tumor-derived S100A9 and CALML5, which is associated with mTORC1 activation. This finding suggests that tasquinimod, an S100A9 inhibitor, could be a viable therapeutic option. Additionally, an interaction between CALML5 and SLPI across tumor and immune areas indicated a potential role in maintaining tumor integrity and mitigating immune-mediated damage. Conversely, patients with longer survival (OS > 3 years) exhibited SERPINA1 as a hub gene linked to estrogen receptor activation, and an interaction between FKBP5 and SESN3 associated with AKT/mTORC1 inhibition within tumor-rich regions. Furthermore, the interaction between MMP11 and COL16A1 in stroma-rich regions suggests that cancer-associated fibroblasts may contribute to improved outcomes. Our study underscores the critical role of spatial gene expression analysis in elucidating the tumor microenvironment and its impact on prognosis in patients undergoing E + L treatment, thereby opening new avenues for targeted interventions.

01 May 2026·CANCER LETTERS

Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy

Article

Author: Hung, Mien-Chie ; Liu, Liang-Chih ; Chao, K S Clifford ; Huang, Wei-Chien ; Huynh, Kieu-Thanh ; Chang, Wei-Chao ; Chang, Ling-Chu ; Jiang, Ciao-Ling ; Li, Yi-Chuan ; Wu, Chen-Shiou ; Huang, Kevin Chih-Yang ; Chen, Hsiao-Fan

Phosphoenolpyruvate carboxykinase 1 (PCK1) is known for its role in gluconeogenesis and the regulation of PCK1 expression was shown to associate with oncogenic activity in pancreatic and colorectal cancers. However, in different cancer types such as liver cancer, PCK1 could function as a tumor suppressor, rendering complication for targeted therapy. In this study, we used breast cancer model to delineate its involvement in malignancy, we found PCK1 associated with oncogenic function to promotes cell proliferation, enhances colony formation, and stimulates DNA synthesis in breast cancer. Mechanistically, we found that PCK1 interacts with Cyclin D3, establishing a positive correlation between PCK1 and Cyclin D3 in clinical breast cancer tissues. Cyclin D3 forms a complex with CDK4/6, implicated in the development of resistance to CDK4/6 inhibitors. We identified PCK1 as a key factor in this resistance. Through an extensive screening process, we identified everolimus and auranofin as inhibitors of PCK1. We found that these drugs, in combination with CDK4/6 inhibitors, exhibit a synergistic effect in suppressing breast cancer. These findings reveal the connection between PCK1 and CDK4/6 inhibitor resistance, offering the possibility for improved treatment options for breast cancer. Interestingly, we also found PCK1 and Cyclin D3 interaction in pancreatic cancer, similar to that in breast cancer, but not in liver cancer. Thus, the results may resolve the puzzle for the role of PCK1 in tumor-promoting or -suppressive role in different cancer types.

410

News (Medical) associated with Everolimus

25 Mar 2026

·allsci.com

Pfizer’s CDK4 atirmociclib cuts progression risk by 40% in second-line metastatic breast cancer trial

Pfizer (NYSE: PFE) reported Phase II results for atirmociclib in HR-positive, HER2-negative metastatic breast cancer, with the FOURLIGHT-1 trial meeting its primary endpoint by demonstrating a 40% reduction in the risk of disease progression or death compared to standard-of-care options. The data mark the first randomized Phase II readout for a selective CDK4 inhibitor in patients whose disease has progressed on prior CDK4/6 inhibitor therapy, a population with limited treatment options and no established targeted retreatment strategy. Trial specifics FOURLIGHT-1 is an open-label, randomized, multicenter Phase II study that enrolled 264 patients across 14 countries with HR-positive, HER2-negative advanced or metastatic breast cancer who had progressed after CDK4/6 inhibitor-based treatment. Patients were randomized to atirmociclib plus fulvestrant versus physician’s choice of fulvestrant alone or everolimus plus exemestane. The primary endpoint was investigator-assessed progression-free survival. Atirmociclib plus fulvestrant reduced the risk of progression or death by 40% versus control, with a hazard ratio of 0.60 (95% CI: 0.440–0.825; p=0.0007). The benefit was consistent across prespecified subgroups, including patients with visceral disease, those with prior CDK4/6 inhibitor treatment lasting less than or more than 12 months, and regardless of which CDK4/6 inhibitor was previously received. More than 90% of enrolled patients initiated atirmociclib within three months of their last CDK4/6 inhibitor treatment, indicating a population with recent disease progression rather than a prolonged treatment-free interval. Overall survival data were not mature, with approximately 20% of participants having had an event at the time of analysis. The safety profile was consistent with prior studies of atirmociclib. Discontinuation due to treatment-emergent adverse events occurred in 6.4% of patients on the atirmociclib arm, and no new safety signals were identified, according to the company. Detailed safety data were not disclosed and are expected at a future medical meeting. Development context Atirmociclib is an oral, selective inhibitor of cyclin-dependent kinase 4 (CDK4), a protein that drives the transition from G1 to S phase of the cell cycle. Unlike currently approved CDK4/6 inhibitors such as palbociclib, ribociclib, and abemaciclib, which inhibit both CDK4 and CDK6, atirmociclib targets CDK4 alone. The rationale for selective CDK4 inhibition centers on the hypothesis that sparing CDK6 may reduce hematologic toxicity, particularly neutropenia, which is the dose-limiting side effect of dual CDK4/6 inhibitors. Whether CDK4 selectivity translates into a clinically distinct efficacy or tolerability profile remains to be established in larger trials. The post-CDK4/6 inhibitor treatment landscape in HR-positive, HER2-negative metastatic breast cancer lacks a consensus targeted retreatment approach. Current options after progression on a CDK4/6 inhibitor include fulvestrant monotherapy, everolimus combined with exemestane, and more recently, agents such as elacestrant, an oral selective estrogen receptor degrader approved by the US FDA in 2023 for patients with ESR1-mutated tumors. The PI3K inhibitor alpelisib combined with fulvestrant is approved for PIK3CA-mutated disease. Capivasertib, an AKT inhibitor, received US FDA approval in 2023 in combination with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered tumors. None of these therapies directly address the question of whether continued cell cycle inhibition through a next-generation mechanism can extend disease control after CDK4/6 inhibitor failure. Pfizer stated that a Phase III registrational study for atirmociclib in the first-line metastatic setting is ongoing, and results from a Phase II neoadjuvant study in early breast cancer will be presented at a future medical meeting. The company did not disclose a timeline for regulatory filing based on the FOURLIGHT-1 data or whether the Phase II results alone would support an accelerated approval pathway. The broader competitive context for next-generation CDK4 inhibitors includes programs from other companies, though atirmociclib is the first to report randomized Phase II data in the post-CDK4/6 inhibitor setting. Pfizer’s decision to advance atirmociclib into first-line and early-stage disease reflects a strategy to position the molecule as a potential replacement for, rather than a successor to, existing CDK4/6 inhibitors across treatment lines. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 2Clinical ResultDrug ApprovalPhase 3Accelerated Approval

24 Mar 2026

·www.biospace.com

Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026

AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will formally introduce its Deciparticle ™ nanomedicine platform and present its advancing clinical pipeline at BIO-Europe Spring 2026, where the company has been selected as a Presenting Company. The presentation will take place at: Event: BIO-Europe Spring 2026 Session: Presenting Company Location: Theater A Date: March 25, 2026 During the session, Sapu Nano will unveil its proprietary Deciparticle ™ platform, a next-generation drug delivery technology engineered to optimize tissue distribution, enhance therapeutic index, and enable intravenous delivery of highly hydrophobic oncology agents. The company will highlight two lead clinical candidates: Sapu003 (Everolimus for Injection) Intravenous formulation of everolimus Designed to overcome limitations of oral exposure and tissue variability Currently in Phase 1 clinical trials Sapu006 (Docetaxel for Injection) Advanced formulation of docetaxel leveraging Deciparticle ™ technology Aimed at improving safety and efficacy versus conventional docetaxel formulations Entering Phase 1 clinical trials “Our Deciparticle ™ platform represents a major step forward in controlling drug distribution at the tissue level,” said Dr. Vuong Trieu, Chief Executive Officer of Sapu Nano. “With Sapu003 and Sapu006 entering Phase 1, we are translating this platform into clinical-stage assets with the potential to significantly improve outcomes in oncology.” The presentation will emphasize: Platform-level advantages of Deciparticle ™ in sub-20 nm nanomedicine design Improved pharmacokinetics and tissue targeting capabilities Reduction of formulation-related toxicities associated with conventional excipients Broad applicability across multiple hydrophobic drug classes BIO-Europe Spring is one of the premier global partnering conferences for the life sciences industry, bringing together biotechnology, pharmaceutical, and investment leaders to foster strategic collaborations and advance innovative therapeutics. Sapu Nano is actively seeking strategic partnerships, co-development opportunities, and regional collaborations to accelerate the clinical development and commercialization of its Deciparticle ™ pipeline. About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG”) through OT-101 through its 45% joint venture, GMP Bio, melanoma (through CA4P) and its wholly owned subsidiary Sapu, and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our 2024 Annual Report on form 10-K filed with the SEC on April 15, 2025. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the Company faces known and unknown risks, including the risk factors described in the Company's 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com

AcquisitionPhase 1

23 Mar 2026

·www.biospace.com

Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting

AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary Sapu Nano will present new data on everolimus toxicology, focusing on tissue concentration–driven effects, at the upcoming Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo , taking place March 22–25, 2026, in San Diego, California. The presentation will be featured during the Poster Session: ADME/Toxicokinetics I : Date: Monday, March 23, 2026 Time (Author Attended): 1:45 PM – 4:15 PM Display Time: 9:00 AM – 4:30 PM Location: Exhibit Hall B, San Diego Convention Center Abstract #: 3539 Poster Board #: K692 Presentation Title: “Everolimus Toxicology: Tissue Concentration Effects” Authors: W. Chang, N. Chang, T. Hoque, and C. Lee Sapu Nano, San Diego, CA This poster presents new findings that elucidate the relationship between tissue-level exposure of everolimus and organ-specific toxicological outcomes, advancing understanding beyond traditional plasma pharmacokinetics. “These data underscore the importance of tissue pharmacokinetics in determining toxicity profiles for mTOR inhibitors such as everolimus,” said Wen-Han Chang PhD, Sr. Manager Nanomedicine. “Our findings provide a foundation for developing improved delivery strategies, including intravenous and nanoparticle-based formulations that better control biodistribution.” The SOT Annual Meeting and ToxExpo is the leading international forum for toxicology, bringing together scientists from academia, industry, and regulatory agencies to present cutting-edge research in safety science and drug development. Sapu Nano’s participation highlights its continued leadership in nanomedicine and advanced drug delivery, with a focus on enhancing therapeutic index through precise control of drug distribution at the tissue level. For more information about the meeting, visit: | #2026SOT | #ToxExpo About Sapu Nano Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG”) through OT-101 through its 45% joint venture, GMP Bio, melanoma (through CA4P) and its wholly owned subsidiary Sapu, and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our 2024 Annual Report on form 10-K filed with the SEC on April 15, 2025. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the Company faces known and unknown risks, including the risk factors described in the Company's 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.: Investor Relations ir@oncotelic.com

Acquisition

100 Deals associated with Everolimus

External Link

KEGG	Wiki	ATC	Drug Bank
D02714	Everolimus	L04AA18 L01XE10	DB01590

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Epilepsy	United States	Novartis Pharmaceuticals Corp.	30 Dec 2021
Epilepsies, Partial	United States	Novartis Pharmaceuticals Corp.	10 Apr 2018
Renal angiomyolipoma with tuberous sclerosis complex	China	Novartis Pharma AG	12 Dec 2016
Breast cancer recurrent	Japan	Novartis Pharma AG	17 Mar 2014
Pancreatic Islet Cell Tumors	China	Novartis Pharma AG	01 Feb 2014
Subependymal Giant Cell Astrocytoma	China	Novartis Pharma AG	01 Feb 2014
Hormone receptor positive HER2 negative breast cancer	United States	Novartis Pharmaceuticals Corp.	20 Jul 2012
Gastro-Enteropancreatic Neuroendocrine Tumor	Japan	Novartis Pharma AG	22 Dec 2011
Tuberous Sclerosis	European Union	Novartis Europharm Ltd.	02 Sep 2011
Tuberous Sclerosis	Iceland	Novartis Europharm Ltd.	02 Sep 2011
Tuberous Sclerosis	Liechtenstein	Novartis Europharm Ltd.	02 Sep 2011
Tuberous Sclerosis	Norway	Novartis Europharm Ltd.	02 Sep 2011
Astrocytoma	United States	Novartis Pharmaceuticals Corp.	29 Oct 2010
Angiomyolipoma	Canada	Novartis Pharmaceuticals Canada, Inc.	15 Mar 2010
Hormone receptor positive breast cancer	European Union	Novartis Europharm Ltd.	02 Aug 2009
Hormone receptor positive breast cancer	Iceland	Novartis Europharm Ltd.	02 Aug 2009
Hormone receptor positive breast cancer	Liechtenstein	Novartis Europharm Ltd.	02 Aug 2009
Hormone receptor positive breast cancer	Norway	Novartis Europharm Ltd.	02 Aug 2009
Neuroendocrine Tumors	European Union	Novartis Europharm Ltd.	02 Aug 2009
Neuroendocrine Tumors	Iceland	Novartis Europharm Ltd.	02 Aug 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Seizures	Phase 3	United States	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Japan	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Australia	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Belgium	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Canada	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Colombia	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	France	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Hungary	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Italy	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017
Seizures	Phase 3	Mexico	Novartis Pharmaceuticals Canada, Inc.	08 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SABCS2025	Phase 1	Breast Cancer RICTOR \| RPTOR	9	Everolimus Nanoparticle (Sapu003) (high-RICTOR / low-RPTOR signature)	athqdpwphz(yjyevbkobg) = zfuokrykjo smpcjllisa (wgrqezlwye ) View more	Positive	11 Dec 2025
NCT03032406 (CLEVER, SABCS2025)	Phase 2	Breast Cancer ER+ \| HER2+ \| CK	51	Hydroxychloroquine (HCQ)	kicdrhxeno(rvjoukslkb) = fhqzzvsypr tckztnqjia (jfojczmkfv ) View more	Positive	11 Dec 2025
				Everolimus (EVE)	-
SABCS2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer Second line	281	Everolimus plus endocrine therapy	swrymfeycc(srpfrwntxv): HR = 1.8 (95.0% CI, 1.07 - 3.04), P-Value = 0.0269 View more	Positive	10 Dec 2025
				Chemotherapy alone or combined with maintenance endocrine therapy
SABCS2025	Not Applicable	Hormone receptor positive HER2 negative breast cancer HR+ \| HER2- \| PI3K/AKT/PTEN pathway alterations	72	≥2 pathway inhibitors sequentially	giwyiwvwzr(roxbwvqbfg) = apbvnafarq sqltxfqzfk (mmlwswkyit, 9 - 28)	Positive	10 Dec 2025
				alpelisib alone	giwyiwvwzr(roxbwvqbfg) = ufgctkqlns sqltxfqzfk (mmlwswkyit, 5 - 8)
ESMO_ASIA2025	Not Applicable	Advanced Neuroendocrine Neoplasm First line	67	Everolimus + Somatostatin analogues	rpdemlmbco(lqmmuwbrwz) = laybitteux osafmhhqnu (toiiyftsxe ) View more	Positive	05 Dec 2025
				Everolimus	rpdemlmbco(lqmmuwbrwz) = fnmdqidcap osafmhhqnu (toiiyftsxe ) View more
NCT03386539 (Pubmed \| JAMA)	Phase 3	Cardiac transplant rejection	211	Everolimus and low-dose tacrolimus	olkvnkekvz(vfcgtkftab): HR = 0.5 (95.0% CI, 0.26 - 0.93) View more	Positive	21 Oct 2025
				Standard-dose tacrolimus and mycophenolate mofetil
JPRN-jRCT1031200023 (JCOG1901, ESMO2025)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor First line	178	Everolimus + Lanreotide	afezljlxpu(vmetnmnjks) = pocqgilgcm rhrlzqrjvj (qftqntpyev ) View more	Positive	17 Oct 2025
				Everolimus	afezljlxpu(vmetnmnjks) = ewjczjfbdo rhrlzqrjvj (qftqntpyev ) View more
ESMO2025	Not Applicable	ER-positive/HER2-negative Breast Cancer Second line ESR1 mutations	75	everolimus + ET (ESR1m)	xfxspezxso(gtexcuxnxy) = eyzwvydksk liiliiwttn (lepccdsnbs ) View more	Positive	17 Oct 2025
				everolimus + ET (ESR1wt)	eekwbtlhto(bnmjsnodpp) = ydxnlvkykg adgetmnuhn (fpgttioili ) View more
NCT05012371 (ESMO2025)	Phase 2	Metastatic Clear Cell Renal Cell Carcinoma Second line	90	Lenvatinib plus Everolimus (Len/eve)	bydnbomdjp(zqceduacuk) = dsdazvpncj nhmmgvjbnc (zvcxhoqfrb ) View more	Positive	17 Oct 2025
				Cabozantinib (cabo)	bydnbomdjp(zqceduacuk) = pomuoapfeh nhmmgvjbnc (zvcxhoqfrb ) View more
NCT03032406 (CLEVER, Pubmed \| Nat Med)	Phase 2	Breast Cancer	51	Hydroxychloroquine (HCQ)	ooecvmhxhd(kkqoxjrjeo) = lisquylshe gkcgyfzcig (monpkfvbxl )	Positive	01 Oct 2025
				Everolimus (EVE)	ooecvmhxhd(kkqoxjrjeo) = phecwqlppk gkcgyfzcig (monpkfvbxl )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis